Amarin Corp Plc (AMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 96

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Equity Offering 15
Amarin Files Registration Statement for Public Offering of ADS 15
Amarin Announces Underwriter's Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 16
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 18
Amarin Completes Public Offering Of Shares For US$121.5 Million 19
Amarin Completes An Underwritten Public Offering Of US$105 Million 21
Debt Offering 23
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Acquisition 27
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc - Key Competitors 28
Amarin Corp Plc - Key Employees 29
Amarin Corp Plc - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 01, 2017: Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations 31
Aug 02, 2017: Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations 33
May 03, 2017: Amarin reports lower Q1 net loss, re-affirms annual guidance 36
Feb 28, 2017: Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations 37
Jan 05, 2017: Amarin announces revenue forecast for 2017 40
Jan 05, 2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 42
Nov 03, 2016: Amarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations 44
Aug 04, 2016: Amarin Reports Second Quarter 2016 Financial Results and Provides Update on Operations 47
May 05, 2016: Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations 50
Feb 25, 2016: Amarin Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Update on Operations 52
Jan 11, 2016: Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook 56
Corporate Communications 58
Jun 30, 2016: Amarin Appoints Michael W. Kalb Chief Financial Officer 58
Jan 21, 2016: Amarin Appoints Craig B. Granowitz Chief Medical Officer and Names Steven Ketchum Chief Scientific Officer 59
Legal and Regulatory 60
Mar 09, 2016: Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation 60
Feb 17, 2016: Request for Continued Stay in Court Proceedings Submitted in Amarin First Amendment Litigation 61
Product News 62
11/14/2016: Pure EPA Vascepa (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Parameters in Statin-Treated Women with Persistent High Triglycerides 62
10/25/2016: Pure EPA Vascepa Now Available in New, Smaller Half-Gram Capsule Size 64
06/12/2017: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides 65
06/11/2016: Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides 66
06/06/2016: Vascepa (Icosapent Ethyl) Data to Be Presented at American Diabetes Association 76th Scientific Sessions 68
05/20/2016: Vascepa (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels 69
05/18/2017: Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care 70
05/11/2016: Vascepa (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions 71
05/03/2017: Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations 72
03/16/2017: Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study 77
03/15/2017: Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology 78
03/08/2016: Amarin's Right to Promote Vascepa Off-Label Affirmed Under First Amendment Litigation Settlement Terms 79
01/05/2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 81
Clinical Trials 83
Sep 13, 2017: Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer 83
Aug 14, 2017: Amarin Provides Update on Vascepa 84
Sep 12, 2016: Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee 86
Aug 31, 2016: Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa 87
Aug 04, 2016: Amarin and FDA Reaffirm Concurrence on REDUCE-IT Through Special Protocol Assessment Agreement Amendment 88
Apr 04, 2016: Amarin Corporation Presents Pre-Clinical Data at American College of Cardiology Meeting on the Effect of EPA Therapy on Endothelial Function 91
Apr 04, 2016: New Clinical Data Presented on Vascepa at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients in Exploratory Studies 92
Mar 31, 2016: Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of Vascepa in Patients With Elevated Triglycerides Despite Statin Therapy 94
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96

List of Tables
Amarin Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarin Corp Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Amarin Files Registration Statement for Public Offering of ADS 15
Amarin Announces Underwriter's Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 16
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 18
Amarin Completes Public Offering Of Shares For US$121.5 Million 19
Amarin Completes An Underwritten Public Offering Of US$105 Million 21
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc, Key Competitors 28
Amarin Corp Plc, Key Employees 29
Amarin Corp Plc, Subsidiaries 30

List of Figures
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Amarin Corp Plc (AMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027